Related Experiment Video
Updated: Jan 11, 2026

Ultrasound Cyclo Plasty in Eyes with Glaucoma
Published on: January 26, 2018
Impact of 0.05% cyclosporine A on visual quality in patients with Post-refractive surgery dry eye
Xuze Wang1, Dejuan Song1, Xiaoying He2
1Eye Center of Second Affiliated Hospital, School of Medicine, Zhejiang Provincial Key Laboratory of Ophthalmology, Zhejiang University, Zhejiang Provincial Clinical Research Center for Eye Diseases. Zhejiang Provincial Engineering Institute on Eye Diseases, Hangzhou, China.
Purpose:
To investigate the effects of 0.05% Cyclosporine A (CsA) eye drops on visual quality including corneal higher-order aberrations (HOAs) in post-refractive surgery dry eye syndrome (DES) patients.
Methods:
This prospective, randomized study involves 52 patients diagnosed with post-refractive surgery DES. The control group (22 eyes) received conventional dry eye therapy (20% deproteinized calf serum, 3% diquafosol tetrasodium eye drops), and the treatment group (30 eyes) received an additional 0.05% CsA. Corneal HOAs, corneal fluorescein staining (CFS), tear break-up time (TBUT), tear meniscus height (TMH), redness index, meibography, Ocular Surface Disease Index (OSDI), and subjective visual quality scores were assessed before and after three months.
Results:
Both groups showed significant improvements (with no significant differences between groups) in TBUT, redness index, and ODSI. Compared with the control group, corneal HOAs, visual quality subjective scores, and CFS scores improved significantly in the treatment group. For the treatment group, Z(3, 1) and Z(4, -2) over 3 mm zone as well as Z(3, 1), Z(4, -2) and Z(4, -4) term over 5 mm zone showed significant changes after three months of treatment.
Conclusion:
The administration of 0.05% CsA significantly improved tear film stability and reduced corneal HOAs, enhancing visual quality in post-refractive surgery DES patients.
Key Messages:
What is known Post-refractive surgery dry eye syndrome (DES) can degrade visual quality due to increased higher-order aberrations (HOAs) and tear film instability. Cyclosporine A (CsA) 0.05% has recognized anti-inflammatory effects and is commonly used to manage various types of DES. What is new The addition of 0.05% CsA to conventional DES treatment significantly improves corneal HOAs and subjective visual quality in post-refractive surgery patients. This study provides quantitative evidence that CsA not only relieves post-refractive DES symptoms but also enhances visual performance through improved tear film stability and optical quality.
Related Concept Videos
Angle Closure Glaucoma: Treatment
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Glaucoma: Overview

